|
Association of rs351855 and rs1983891 Polymorphisms with Prostate Cancer in the Iranian Population
|
Shabnam Khazraei1    , Seyed Abdolhamid Angaji2 , Behnaz Beikzadeh3 , Mitra Salehi4 , Raheleh Roudi5 , Behzad Narouie6 |
1- MSc student, Department of Biological Sciences, Islamic Azad University, North Tehran, Tehran, Iran. & MSc student, Department of Biological Sciences, Islamic Azad University, North Tehran, Tehran, Iran.
2- Associate Professor, Department of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran & Associate Professor, Department of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran , ershad110@yahoo.com
3- Ph.D. Candidate, Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran. & Ph.D. Candidate, Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
4- Assistant Professor, Department of Biological Sciences, Islamic Azad University, North Tehran, Tehran, Iran. & Assistant Professor, Department of Biological Sciences, Islamic Azad University, North Tehran, Tehran, Iran.
5- Ph.D., Department of Radiology, Faculty of Molecular Imaging, Stanford University, CA94305, USA. & Ph.D., Department of Radiology, Faculty of Molecular Imaging, Stanford University, CA94305, USA. ORCID ID: 0000-0001-5023-4743
6- MD., Department of Urology, Zahedan University of Medical Sciences, Zahedan, Iran. & MD., Department of Urology, Zahedan University of Medical Sciences, Zahedan, Iran. |
|
|
Abstract: (787 Views) |
Background and Aim: Prostate Cancer (PC) is one of the most common cancers and the second leading cause of death in Iranian men. Several factors such as age, endogenous hormone balance, genetic factors and environmental factors are involved in PC incidence. The aim of this study was to investigate the association of rs351855 and rs1983891 polymorphisms with prostate cancer risk in Iranian population.
Materials and Methods: In this case-control study 185 peripheral blood samples were taken from 101 patients with prostate cancer and 84 healthy individuals. For SNP genotyping in each sample, Tetra-ARMs PCR method was used.
Results: According to the multi-stage method, 58 individuals were selected in the first stage. p-value<0.4 was considered significant. In relation to rs351855, there was a significant difference between the case and control groups (P<0.16), but, there was no significant difference between the groups in regard to rs1983891 (P<0.62). Therefore, rs1983891 was eliminated at this stage. In the second stage, all samples (184 samples) were analyzed in relation to rs351855 at a significance level of P<0.05. A significant difference was observed between the two groups of case and control in relation to rs351855 polymorphism in all samples (P<0.00). In this study, allelic and genotypic frequencies were investigated in multiplicative and additive genetic models. Our data showed a significant relationship between the multiplicative model allele (A) and the risk of prostate cancer, also the data indicated that the additive model AA vs GG and AG vs GG were associated with PC. On the other hand, this polymorphism was associated with all three levels of PSA and Gleason score.
Conclusion: In the present study rs351855 polymorphism was associated with the risk of prostate cancer in Iran, on the contrary, rs1983891 polymorphism was not associated with prostate cancer risk. rs351855 may be considered as a potential biomarker for the screening of prostate cancer.
|
|
| Keywords: Prostate cancer, Polymorphism, Screening |
|
|
Full-Text [PDF 740 kb]
(250 Downloads)
|
Type of Study: Original Research |
Subject:
Molecular Medicine and Genetics
Received: 2022/10/30 | Accepted: 2023/11/4 | Published: 2024/09/18
|
|
|
|
|
|
|
| References |
1. Salavati, L. S., Tafvizi, F., & Manjili, H. K. (2017). The association between MMP2− 1306 C> T (rs243865) polymorphism and risk of prostate cancer. Ir. J. Med. Sci. (1971-), 186(1), 103-111. [ DOI:10.1007/s11845-016-1492-9] [ PMID] 2. Farhood, B., Geraily, G., & Alizadeh, A. (2018). Incidence and mortality of various cancers in Iran and compare to other countries: a review article. Iran. J. Public Health, 47(3), 309. 3. Grozescu, T., & Popa, F. (2017).Prostate cancer between prognosis and adequate/proper therapy. JML, 10(1), 5. 4. Frame, F. M., & Maitland, N. J. (2019). Epigenetic control of gene expression in the normal and malignant human prostate: A rapid response which promotes therapeutic resistance. Int. J. Mol. Sci., 20(10), 2437. [ DOI:10.3390/ijms20102437] [ PMID] [ ] 5. Mistry, K., & Cable, G. (2003). Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. JABFM, 16(2), 95-101. [ DOI:10.3122/jabfm.16.2.95] [ PMID] 6. Liu, G., Chen, T., Ding, Z., Wang, Y., Wei, Y., & Wei, X. (2021). Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment. Cell Prolif., 54(4), e13009. [ DOI:10.1111/cpr.13009] [ PMID] [ ] 7. Shaw, G. (2013). Polymorphism and single nucleotide polymorphisms (SNP s). BJU international, 112(5), 664-665. [ DOI:10.1111/bju.12298] [ PMID] 8. Hirschhorn, J. N., & Daly, M. J. (2005). Genome-wide association studies for common diseases and complex traits. Nat. Rev. Genet., 6(2), 95-108. [ DOI:10.1038/nrg1521] [ PMID] 9. Beikzadeh, B., Angaji, S. A., & Abolhasani, M. (2020). Association study between common variations in some candidate genes and prostate adenocarcinoma predisposition through multi-stage approach in Iranian population. BMC Med. Genet., 21(1), 1-10. [ DOI:10.1186/s12881-020-01014-0] [ PMID] [ ] 10. FitzGerald, L. M., Karlins, E., Karyadi, D. M., Kwon, E. M., Koopmeiners, J. S., Stanford, J. L., & Ostrander, E. A. (2009). Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis. PCAN, 12(2), 192-197. [ DOI:10.1038/pcan.2008.46] [ PMID] [ ] 11. Mistry, K., & Cable, G. (2003). Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. JABFM, 16(2), 95-101. [ DOI:10.3122/jabfm.16.2.95] [ PMID] 12. Munkley, J., Li, L., Krishnan, S. G., Hysenaj, G., Scott, E., Dalgliesh, C., ... & Elliott, D. J. (2019). Androgen-regulated transcription of ESRP2 drives alternative splicing patterns in prostate cancer. Elife, 8.
.028 [ DOI:10.7554/eLife.47678] 13. Lawrence, M. G., Pidsley, R., Niranjan, B., Papargiris, M., Pereira, B. A., Richards, M., ... & Clark, S. J. (2020). Alterations in the methylome of the stromal tumour microenvironment signal the presence and severity of prostate cancer. Clin. Epigenetics, 12(1), 1-18. [ DOI:10.1186/s13148-020-00836-2] [ PMID] [ ] 14. Scott, E., & Munkley, J. (2019). Glycans as biomarkers in prostate cancer. Int. J. Mol. Sci., 20(6), 1389. [ DOI:10.3390/ijms20061389] [ PMID] [ ] 15. Li, J. P., Huang, H. C., Yang, P. J., Chang, C. Y., Chao, Y. H., Tsao, T. C. Y., ... & Yang, S. F. (2020). FGFR4 Gene Polymorphism Reduces the Risk of Distant Metastasis in Lung Adenocarcinoma in Taiwan. IJERPH, 17(16), 5694. [ DOI:10.3390/ijerph17165694] [ PMID] [ ] 16. Xu, B., Tong, N., Chen, S. Q., Hua, L. X., Wang, Z. J., Zhang, Z. D., & Chen, M. (2011). FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: a meta-analysis of 2618 cases and 2305 controls. BMC cancer, 11(1), 1-6. [ DOI:10.1186/1471-2407-11-84] [ PMID] [ ] 17. Chen, L., Lei, Z., Ma, X., Huang, Q., Zhang, X., Zhang, Y., ... & Zheng, T. (2016). Prognostic significance of fibroblast growth factor receptor 4 polymorphisms on biochemical recurrence after radical prostatectomy in a Chinese population. Sci. Rep., 6(1), 1-6. [ DOI:10.1038/srep33604] [ PMID] [ ] 18. Van den Broeck, T., Joniau, S., Clinckemalie, L., Helsen, C., Prekovic, S., Spans, L., ... & Claessens, F. (2014). The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making. Biomed Res. Int., 2014. [ DOI:10.1155/2014/627510] [ PMID] [ ] 19. Peng, T., Sun, Y., Lv, Z., Zhang, Z., Su, Q., Wu, H., ... & Mi, Y. (2021). Effects of FGFR4 G388R, V10I polymorphisms on the likelihood of cancer. Sci. Rep., 11(1), 1-12. [ DOI:10.1038/s41598-020-80146-y] [ PMID] [ ] 20. Zhao, J., Yang, T., & Li, L. (2020). LncRNA FOXP4-AS1 is involved in cervical cancer progression via regulating miR-136-5p/CBX4 axis. Onco Targets Ther, 13, 2347. [ DOI:10.2147/OTT.S241818] [ PMID] [ ] 21. Huang, C., Deng, H., Wang, Y., Jiang, H., Xu, R., Zhu, X., ... & Zhao, X. (2019). Circular RNA circABCC4 as the ceRNA of miR‐1182 facilitates prostate cancer progression by promoting FOXP4 expression. JCMM, 23(9), 6112-6119. [ DOI:10.1111/jcmm.14477] [ PMID] [ ] 22. Li, X. H., Xu, Y., Yang, K., Shi, J. J., Zhang, X., Yang, F., ... & Yang, Z. (2015). Association of THADA, FOXP4, GPRC6A/RFX6 genes and 8q24 risk alleles with prostate cancer in Northern Chinese men. Journal of BU ON.: Journal of B.U.ON., 20(5), 1223-1228. 23. Lindström, S., Schumacher, F. R., Campa, D., Albanes, D., Andriole, G., Berndt, S. I., ... & Kraft, P. (2012). Replication of Five Prostate Cancer Loci Identified in an Asian Population-Results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3) Association of Prostate Cancer Loci across Ethnicities. CEBP, 21(1), 212-216. [ DOI:10.1158/1055-9965.EPI-11-0870-T] [ PMID] [ ] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Ethics code: IR.IAU.TNB.REC.1401.003
Khazraei S, Angaji S A, Beikzadeh B, Salehi M, Roudi R, Narouie B. Association of rs351855 and rs1983891 Polymorphisms with Prostate Cancer in the Iranian Population. SJKU 2024; 29 (3) :26-37 URL: http://sjku.muk.ac.ir/article-1-7642-en.html
|
